Novanta (NOVT) Q2 2026 Earnings Call Transcript
Novanta Inc. (NOVT) reported Q2 2026 revenue of $265.8 million, up 10.3% (9.3% organic). Adjusted EPS was $0.89, up 17.1%, with adjusted EBITDA of $60.7 million. The company raised 2026 guidance for revenue ($1.13B-$1.14B) and adjusted EBITDA ($273M-$278M) after completing the Riverpoint Medical acquisition, expected to add ~$65M revenue and ~$25M adjusted EBITDA in 2H26.
How this was made
The 30-second read
Why it matters
The most tradable elements are the explicit FY2026 guidance ranges, the quantified Riverpoint Medical contribution for 2H26, and management’s margin improvement outlook versus near-term life-sciences decline.
Market read
This is a guidance and acquisition-integration update with quantified financial ranges, likely driving near-term revisions to 2026 growth and margin expectations.
What to watch
The call notes factory redundancy and logistics/tariff-related costs; traders may underweight how these could persist longer than management’s gross-margin improvement path implies.
Background
Novanta reported Q2 2026 results and discussed integration of Riverpoint Medical, plus capacity expansion and business-unit performance across automation and medical solutions.
Ticker impact
Novanta guided FY2026 revenue to $1.13B-$1.14B and adjusted EPS to $3.68-$3.74, alongside Riverpoint Medical contribution expectations.
Bias upward on expectation of stronger growth and cash generation, but with downside risk from life-sciences commoditization and margin headwinds.
The call provides specific FY2026 guidance ranges, Riverpoint Medical revenue and EBITDA add, and margin improvement commentary, but also flags near-term life-sciences decline and transformation costs that can temper the multiple.
Market effects
Signals continued demand strength in precision robotics and semiconductor-related automation, while highlighting life-sciences commoditization pressure.
China capacity doubling plan for air bearing spindles may support regional supply chain and production utilization expectations.
Reinforces the AI infrastructure and robotics capex theme via stated generative AI exposure and servo drive orders for training facilities.
Counterpoint
Despite strong bookings and guidance, the disclosed life-sciences decline and transformation costs could cause margin delivery risk, making the stock vulnerable to multiple compression if execution slips.
Key entities
- companyNovanta Inc.
Precision robotics and medical solutions provider issuing Q2 2026 results and FY2026 guidance, including Riverpoint Medical integration impacts.
- acquired businessRiverpoint Medical
Acquisition expected to add about $65M revenue and $25M adjusted EBITDA in 2H26, and expand medical consumables to about 25% of annualized sales.
- executiveMatthijs Glastra
CEO who emphasized record new product momentum and an improving trajectory.
- executiveRobert Buckley
CFO who discussed gross margin drivers and near-term life-sciences commoditization risks.
